Diagonal Bio AB (DIABIO) - Total Liabilities
Based on the latest financial reports, Diagonal Bio AB (DIABIO) has total liabilities worth Skr2.13 Million SEK (≈ $229.54K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DIABIO operating cash flow to assess how effectively this company generates cash.
Diagonal Bio AB - Total Liabilities Trend (2020–2024)
This chart illustrates how Diagonal Bio AB's total liabilities have evolved over time, based on quarterly financial data. See Diagonal Bio AB (DIABIO) net assets for net asset value and shareholders' equity analysis.
Diagonal Bio AB Competitors by Total Liabilities
The table below lists competitors of Diagonal Bio AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SDM SE
XETRA:75S
|
Germany | €12.80 Million |
|
Thunder Power Holdings, Inc.
NASDAQ:AIEV
|
USA | $7.03 Million |
|
Volvere PLC
LSE:VLE
|
UK | GBX9.80 Million |
|
Logistics Development Group PLC
LSE:LDG
|
UK | GBX375.00K |
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
Indonesia | Rp17.84 Billion |
|
Watkin Jones PLC
LSE:WJG
|
UK | GBX187.44 Million |
|
Alternative Income REIT PLC
LSE:AIRE
|
UK | GBX43.83 Million |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
Korea | ₩19.59 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Diagonal Bio AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DIABIO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diagonal Bio AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diagonal Bio AB (2020–2024)
The table below shows the annual total liabilities of Diagonal Bio AB from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr2.54 Million ≈ $273.24K |
-65.03% |
| 2023-12-31 | Skr7.26 Million ≈ $781.40K |
+161.47% |
| 2022-12-31 | Skr2.78 Million ≈ $298.85K |
+29.52% |
| 2021-12-31 | Skr2.14 Million ≈ $230.73K |
+98.52% |
| 2020-12-31 | Skr1.08 Million ≈ $116.23K |
-- |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more